Pharmacyclics' (PCYC +1.7%) Phase III trial of its ibrutinib drug for treating leukiemia has enrolled a 5th patient, thereby triggering a milestone payment of $50M from J&J (NYSE:JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (PR)